Go Pro
NASDAQ:EDSA

Edesa Biotech Q3 2025 Earnings Report

Edesa Biotech logo
$4.07 -0.04 (-0.97%)
Closing price 09/22/2026 04:00 PM Eastern
Extended Trading
$4.15 +0.08 (+1.94%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edesa Biotech EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Edesa Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Edesa Biotech Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Edesa Biotech's next earnings date is estimated for Friday, December 11, 2026, based on past reporting schedules.

Conference Call Resources

Edesa Biotech Earnings Headlines

Edesa Biotech (NASDAQ:EDSA) Rating Increased to Sell at Wall Street Zen
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
Edesa Biotech prices $25M equity offering
See More Edesa Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email.

About Edesa Biotech

Edesa Biotech (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immune-related diseases. The company’s research programs are centered on biologic and anti-inflammatory treatments intended to address conditions for which existing treatment options may be limited.

Edesa’s lead development program has included EB01, a topical, non-steroidal therapy being investigated for chronic allergic contact dermatitis, a persistent inflammatory skin condition. The company has also pursued EB05, an antibody-based treatment candidate for inflammatory complications associated with acute respiratory distress, including programs evaluated in connection with COVID-19.

Founded in Canada, Edesa has conducted its development activities through clinical research and regulatory programs in North America and other international jurisdictions. The company is led by Dr. Par Nijhawan, who serves as chief executive officer and has been involved in the company’s biopharmaceutical development strategy.

View Edesa Biotech Profile